Skip to main content
SpringerLink
Log in

Behçet’s Syndrome: Clinical Presentations Affecting Prognosis and Survival

  • Chapter
  • First Online:
Autoimmune Diseases

  • 1390 Accesses

Abstract

Behçet’s syndrome (BS) is a multisystem vasculitis with unknown etiology and a unique geographic distribution. It has a high prevalence in the Middle-Eastern and Mediterranean countries. Recurrent skin-mu cosa lesions and sight-threatening panuveitis are the disease hallmarks. BS may also involve joints, vessels of all types and size, the central nervous system (CNS), and the gastrointestinal system. The disease course is characterized by exacerbations and remissions. The disease runs a more severe course among young males, and the severity diminishes with age. Males are more severely affected. Ocular, vascular, and CNS involvement are the main causes of morbidity. This may result in irreversible damage such as loss of useful vision, neurological disability, and potentially fatal bleeding from pulmonary artery aneurysm or Budd–Chiari syndrome. Mortality rate is also increased in BS, especially in young males. Large vessel and parenchymal CNS disease are the main causes of death. However, an early and aggressive approach can lead to better treatment for the ocular and vascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siva A, Yazici H. Behçet’s syndrome. Neurological involvement in systemic autoimmune disease. In: Erkan D, Levine SR, eds. Handbook of Systemic Autoimmune Diseases, vol. 3. Amsterdam: Elsevier; 2004:193.

    Google Scholar 

  2. Mat C, Demirkesen C, Melikoglu M, Yazici H. Behçet’s syndrome. The skin in systemic autoimmune disease. In: Piercarlo Sarzi-Puttini, Doria A, Giampiero Girolomoni, Kuhn A, eds. Handbook of Systemic Autoimmune Diseases, vol. 5. Amsterdam: Elsevier; 2006:185.

    Chapter  Google Scholar 

  3. Yazici H. The place of Behçet’s syndrome among the autoimmune diseases. Int Rev Immunol. 1997;14:1-10.

    Article  PubMed  CAS  Google Scholar 

  4. Fresko I, Melikoglu M, Kural-Seyahi, et al. Behcet’s syndrome: pathogenesis, clinical manifestations and treatment in Vasculitis by Gene. In: Ball GV, Bridges SL, eds. Vasculitis. 2nd ed. New York: Oxford University Press; 2008;461-480.

    Google Scholar 

  5. Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803-806.

    Article  PubMed  Google Scholar 

  6. Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984;43:783-789.

    Article  PubMed  CAS  Google Scholar 

  7. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.

    Article  Google Scholar 

  8. Soy M, Erken E, Konca K, Ozbek S. Smoking and Behcet’s disease. Clin Rheumatol. 2000;19:508-509.

    Article  PubMed  CAS  Google Scholar 

  9. Oh SH, Han EC, Lee JH, et al. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clin Exp Dermatol. 2009;34:e208-e212.

    Article  PubMed  CAS  Google Scholar 

  10. Mansur AT, Kocaayan N, Serdar ZA, et al. Giant oral ulcers of Behçet’s disease mimicking squamous cell carcinoma. Acta Derm Venereol. 2005;85:532-534.

    PubMed  Google Scholar 

  11. Hamza M. Juvenile Behçet’s disease. In: Wechsler B, Godeau P, eds. Behçet’s Disease. Amsterdam: Excerpta Medica; 1993:377-380.

    Google Scholar 

  12. Mat MC, Goksugur N, Engin B, et al. The frequency of scarring after genital ulcers in Behçet’s syndrome: a prospective study. Int J Dermatol. 2006;45:554-556.

    Article  PubMed  Google Scholar 

  13. Hatemi I, Hatemi G, Celik AF, et al. Frequency of pathergy phenomenon and other features of Behçet’s syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008;26(4 Suppl 50):S91-S95.

    PubMed  CAS  Google Scholar 

  14. Ergun T, Gürbüz O, Dogusoy G, Mat C, Yazici H. Histopathologic features of the spontaneous pustular lesions of Behçet’s syndrome. Int J Dermatol. 1998;37:194-196.

    Article  PubMed  CAS  Google Scholar 

  15. Diri E, Mat C, Hamuryudan V, et al. Papulopustular skin lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001;60:1074-1076.

    Article  PubMed  CAS  Google Scholar 

  16. Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis. 2004;63:1450-1452.

    Article  PubMed  CAS  Google Scholar 

  17. Yazici H. The lumps and bumps of Behçet’s syndrome. Autoimmun Rev. 2004;3(Suppl 1):S53-S54.

    PubMed  Google Scholar 

  18. Demirkesen C, Tüzüner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol. 2001;116:341-346.

    Article  PubMed  CAS  Google Scholar 

  19. Tunc R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Behçet’s syndrome. Ann Rheum Dis. 2004;63:1693-1694.

    Article  PubMed  CAS  Google Scholar 

  20. Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet’s disease: a cross sectional study by exploratory factor analysis. J Rheumatol. 2002;29:2393-2396.

    PubMed  Google Scholar 

  21. Yazici H, Tüzün Y, Tanman AB, et al. Male patients with Behçet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol. 1985;3:137-141.

    PubMed  CAS  Google Scholar 

  22. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum. 2001;44:2686-2692.

    Article  PubMed  CAS  Google Scholar 

  23. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-450.

    PubMed  CAS  Google Scholar 

  24. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet’s syndrome. Rheumatology (Oxford). 2006;45:348-352.

    Article  CAS  Google Scholar 

  25. Yazici H, Ozyazgan Y. Medical management of Behcet’s syndrome. Dev Ophthalmol. 1999;31:118-131.

    Article  PubMed  CAS  Google Scholar 

  26. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet’s syndrome: a randomized, double blind trial. Br J Rheumatol. 1991;30:395-396.

    Article  PubMed  CAS  Google Scholar 

  27. Ergun T, Gurbuz O, Yurdakul S, Hamuryudan V, Bekiroglu N, Yazici H. Topical cyclosporine-A for treatment of oral ulcers of Behcet’s syndrome. Int J Dermatol. 1997;36:720.

    Article  PubMed  CAS  Google Scholar 

  28. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum. 1996;39:2062-2065.

    Article  PubMed  CAS  Google Scholar 

  29. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.

    PubMed  CAS  Google Scholar 

  30. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, ­placebo-controlled, cross-over study. J Dermatol. 2002;29:267-279.

    PubMed  CAS  Google Scholar 

  31. Yurdakul S, Yazici H, Tuzun Y, et al. The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis. 1983;42:505-515.

    Article  PubMed  CAS  Google Scholar 

  32. Volpe A, Caramaschi P, Marchetta A, Desto E, Arcar G. Pseudoseptic arthritis in a patient with Behçet’s disease. Clin Exp Rheumatol. 2006;24:S123.

    PubMed  CAS  Google Scholar 

  33. Humby F, Gullick N, Kelly S, Pitzalis C, Oakley SP. A synovial pathergy reaction leading to a pseudo-septic arthritis and a diagnosis of Behçet’s disease. Rheumatology (Oxford). 2008;47:1255-1256.

    Article  CAS  Google Scholar 

  34. Hatemi G, Fresko I, Tascilar K, et al. Increased enthesopathy among Behçet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 2008;58:1539-1545.

    Article  PubMed  Google Scholar 

  35. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behcet’s syndrome. J Rheumatol. 1994;21:1098-1100.

    PubMed  CAS  Google Scholar 

  36. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322:281-285.

    Article  PubMed  CAS  Google Scholar 

  37. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769-774.

    Article  PubMed  CAS  Google Scholar 

  38. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373-380.

    Article  PubMed  Google Scholar 

  39. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102:317-321.

    PubMed  CAS  Google Scholar 

  40. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243:1147-1152.

    Article  PubMed  Google Scholar 

  41. Mamo JG, Baghdassarian A. Behcet’s disease. Arch Ophthalmol. 1964;71:38-48.

    Google Scholar 

  42. Mishima S, Masuda K, Izawa Y, Mochizuke M, Namba K. Behçet’s disease in Japan: ophthalmological aspects. Trans Am Ophthalmol Soc. 1979;77:225-279.

    PubMed  CAS  Google Scholar 

  43. Benezra D, Cohen E. Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol. 1986;70:589-592.

    Article  PubMed  CAS  Google Scholar 

  44. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-243.

    Article  PubMed  CAS  Google Scholar 

  45. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586-589.

    Article  PubMed  CAS  Google Scholar 

  46. Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(4 Suppl 50):S84-S90.

    PubMed  CAS  Google Scholar 

  47. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320-335.

    Article  PubMed  CAS  Google Scholar 

  48. Seyahi E, Ugurlu S, Ozyazgan Y, et al. Interferon α 2b in Behçet’s syndrome with severe ocular involvement. Arthritis Rheum. 2005;52(Suppl 9):S647.

    Google Scholar 

  49. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.

    PubMed  CAS  Google Scholar 

  50. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140:404-406.

    PubMed  CAS  Google Scholar 

  51. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478-2484.

    Article  PubMed  CAS  Google Scholar 

  52. Hamza M. Large artery involvement in Behcet’s disease. J Rheumatol. 1987;14:554-559.

    PubMed  CAS  Google Scholar 

  53. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet’s disease. J Rheumatol. 1992;19:402-410.

    PubMed  CAS  Google Scholar 

  54. Düzgün N, Ateş A, Aydintuğ OT, Demir O, Olmez U. Characteristics of vascular involvement in Behçet’s disease. Scand J Rheumatol. 2006;35:65-68.

    Article  PubMed  Google Scholar 

  55. Melikoglu M, Ugurlu S, Tascilar K, et al. Large vessel involvement in Behcet’s syndrome: a retrospective survey. Ann Rheum Dis. 2008;67(Suppl II):67.

    Google Scholar 

  56. Husain SJ, Sadiq F, Zubairi AB, Khan JA. Massive unilateral chylous pleural effusion: a rare initial presentation of Behcet’s disease. Singapore Med J. 2006;47:978-980.

    PubMed  CAS  Google Scholar 

  57. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary vascular involvement in Behcet’s ­syndrome. Arthritis Rheum. 2007;56(Suppl 9):S357.

    Google Scholar 

  58. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behçet’s ­syndrome: a report of 24 cases. Br J Rheumatol. 1994;33:48-51.

    Article  PubMed  CAS  Google Scholar 

  59. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med. 2004;117:867-870.

    Article  PubMed  Google Scholar 

  60. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common ­complication of Behçet’s disease. Am J Gastroenterol. 1997;92:858-862.

    PubMed  CAS  Google Scholar 

  61. Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16:790-795.

    Article  PubMed  CAS  Google Scholar 

  62. Tüzün H, Beşirli K, Sayin A, Yazici H, et al. Management of aneurysms in Behçet’s ­syndrome: an analysis of 24 patients. Surgery. 1997;121:150-156.

    Article  PubMed  Google Scholar 

  63. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain. 1999;122:2171-2182.

    Article  PubMed  Google Scholar 

  64. Siva A, Kantarci OH, Saip S, et al. Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248:95-103.

    Article  PubMed  CAS  Google Scholar 

  65. Saip S, Siva A, Altintas A, et al. Headache in Behçet’s syndrome. Headache. 2005;45:911-919.

    Article  PubMed  Google Scholar 

  66. Oktem-Tanör O, Baykan-Kurt B, Gürvit IH, Akman-Demir G, Serdaroğlu P. Neuropsychological follow-up of 12 patients with neuro-Behçet disease. J Neurol. 1999;246:113-119.

    Article  PubMed  Google Scholar 

  67. Seyahi E, Ozdogan H, Uğurlu S, et al. The outcome children with Behçet’s syndrome. Clin Exp Rheumatol. 2004;22(4 Suppl 34):116.

    Google Scholar 

  68. Fujikado T, Imagawa K. Dural sinus thrombosis in Behçet’s disease – a case report. Jpn J Ophthalmol. 1994;38(4):411-416.

    PubMed  CAS  Google Scholar 

  69. Erdem H, Dinc A, Pay S, Simsek I, Uysal Y. A neuro-Behcet’s case complicated with intracranial hypertension successfully treated by a lumboperitoneal shunt. Joint Bone Spine. 2006;73:200-201.

    Article  PubMed  Google Scholar 

  70. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha – a new therapeutic option in refractory juvenile Behçet’s disease with CNS involvement. Rheumatology (Oxford). 2008;47:1051-1053.

    Article  CAS  Google Scholar 

  71. Chroni E, Monastirli A, Polychronopoulos P, et al. Epileptic seizures as the sole manifestation of neuro-Behçet’s disease: complete control under interferon-alpha treatment. Seizure. 2008;17:744-747.

    Article  PubMed  Google Scholar 

  72. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League against rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68:1528-1534.

    Article  PubMed  CAS  Google Scholar 

  73. Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behçet’s disease: a systematic review. Chest. 2000;118:479-487.

    Article  PubMed  CAS  Google Scholar 

  74. Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet’s syndrome. Rheumatology (Oxford). 2008;47:472-475.

    Article  CAS  Google Scholar 

  75. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Behçet’s syndrome. Semin Arthritis Rheum. 2008;38:1-12.

    Article  PubMed  CAS  Google Scholar 

  76. Seyahi E, Yazici H. Atherosclerosis in Behçet’s syndrome. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S1-S5.

    PubMed  CAS  Google Scholar 

  77. Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behcet’s syndrome: a controlled study. Ann Rheum Dis. 1996;55:208-210.

    Article  PubMed  CAS  Google Scholar 

  78. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behcet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum. 1981;24:103-106.

    Article  PubMed  CAS  Google Scholar 

  79. Postema PT, den Haan P, van Hagen PM, van Blankenstein M. Treatment of colitis in Behcet’s disease with thalidomide. Eur J Gastroenterol Hepatol. 1996;8:929-931.

    PubMed  CAS  Google Scholar 

  80. Celik AF, Kural-Seyahi E, Cosgun S, Hamuryudan V, Yazici H. Thalidomide in azathioprine resistant gastrointestinal Behçet’s syndrome; 3 cases. Clin Exp Rheumatol. 2004;22(Suppl 34):S121.

    Google Scholar 

  81. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725-728.

    Article  PubMed  CAS  Google Scholar 

  82. Lee KS, Kim SJ, Lee BC, Yoon DS, Lee WJ, Chi HS. Surgical treatment of intestinal Behcet’s disease. Yonsei Med J. 1997;38:455-460.

    PubMed  CAS  Google Scholar 

  83. Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62:2806-2812.

    Article  PubMed  CAS  Google Scholar 

  84. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet’s disease. Semin Arthritis Rheum. 1998;27:197-217.

    Article  PubMed  CAS  Google Scholar 

  85. Benamour S, Zeroual B, Bennis R, Amraoui A, Bettal S. Behçet’s disease. 316 cases. Presse Méd. 1990;19:1485-1489.

    PubMed  CAS  Google Scholar 

  86. Yamamoto S, Toyokawa H, Matsubara J, et al. A nation-wide survey of Behçet’s disease in Japan, 1. Epidemiological survey. Jpn J Ophthalmol. 1974;18:282-290.

    Google Scholar 

  87. Park KD, Bang D, Lee ES, Lee SH, Lee S. Clinical study on death in Behçet’s disease. J Korean Med Sci. 1993;8:241-245.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, University of Istanbul, Istanbul, 36098, Turkey

    Emire Seyahi

Authors
  1. Emire Seyahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koray Tascilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hasan Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emire Seyahi .

Editor information

Editors and Affiliations

  1. Rayne Institute, Lupus Research Unit, St. Thomas' Hospital, London, SE1 7EH, United Kingdom

    Munther A. Khamashta

  2. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Seyahi, E., Tascilar, K., Yazici, H. (2011). Behçet’s Syndrome: Clinical Presentations Affecting Prognosis and Survival. In: Khamashta, M., Ramos-Casals, M. (eds) Autoimmune Diseases. Springer, London. https://doi.org/10.1007/978-0-85729-358-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-358-9_11

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-357-2

  • Online ISBN: 978-0-85729-358-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation